Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene
- PMID: 15980340
- PMCID: PMC1168698
- DOI: 10.1128/AAC.49.7.2710-2715.2005
Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene
Abstract
A new recombinant phenotyping method was developed for the analysis of drug resistance mutations in human cytomegalovirus (CMV). CMV strain T2211 was derived from strain AD169 by inserting unique restriction sites and a secreted alkaline phosphatase (SEAP) reporter gene for rapid viral quantitation. Specific viral UL97 and pol gene mutations were transferred by recombination into T2211, and their drug resistance phenotypes (for ganciclovir, foscarnet, or cidofovir) were determined by the drug concentrations required to reduce supernatant SEAP activity by 50% (IC50). Changes in the IC50 conferred by the mutations tested (UL97 M460V, C592G, A594V, and L595S and pol del981-2) were similar to those previously reported in marker transfer and conventional plaque reduction assays. The combination of UL97 C592G and pol del981-2 conferred much higher ganciclovir resistance than either mutation alone. The UL97 polymorphism D605E had no measurable effect on ganciclovir susceptibility, alone or in combination with common UL97 resistance mutations. Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate.
Figures




Similar articles
-
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.J Clin Virol. 2007 Feb;38(2):120-5. doi: 10.1016/j.jcv.2006.11.005. Epub 2006 Dec 8. J Clin Virol. 2007. PMID: 17157554
-
Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Antimicrob Agents Chemother. 2010 Jun;54(6):2371-8. doi: 10.1128/AAC.00186-10. Epub 2010 Apr 12. Antimicrob Agents Chemother. 2010. PMID: 20385869 Free PMC article.
-
Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir.J Infect Dis. 2002 Jan 15;185(2):162-9. doi: 10.1086/338362. Epub 2001 Dec 17. J Infect Dis. 2002. PMID: 11807689
-
Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir.Rev Med Virol. 2008 Jul-Aug;18(4):233-46. doi: 10.1002/rmv.574. Rev Med Virol. 2008. PMID: 18383425 Review.
-
The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.Infect Disord Drug Targets. 2011 Oct;11(5):504-13. doi: 10.2174/187152611797636668. Infect Disord Drug Targets. 2011. PMID: 21827431 Free PMC article. Review.
Cited by
-
Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens.Antimicrob Agents Chemother. 2007 Nov;51(11):4160-2. doi: 10.1128/AAC.00736-07. Epub 2007 Aug 20. Antimicrob Agents Chemother. 2007. PMID: 17709468 Free PMC article.
-
Analysis of Ganciclovir-Resistant Cytomegalovirus Infection Caused by the UL97 Gene Mutation in Codons 460 and 520 in Pediatric Patients: A Case Series.Open Forum Infect Dis. 2019 Nov 4;6(11):ofz480. doi: 10.1093/ofid/ofz480. eCollection 2019 Nov. Open Forum Infect Dis. 2019. PMID: 32528998 Free PMC article.
-
Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.Antiviral Res. 2017 Feb;138:57-60. doi: 10.1016/j.antiviral.2016.12.003. Epub 2016 Dec 8. Antiviral Res. 2017. PMID: 27940027 Free PMC article.
-
Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy.J Clin Virol. 2011 Apr;50(4):287-91. doi: 10.1016/j.jcv.2011.01.004. Epub 2011 Feb 3. J Clin Virol. 2011. PMID: 21295516 Free PMC article.
-
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.Antiviral Res. 2011 Nov;92(2):313-8. doi: 10.1016/j.antiviral.2011.08.019. Epub 2011 Sep 1. Antiviral Res. 2011. PMID: 21906628 Free PMC article.
References
-
- Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583. - PubMed
-
- Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39. - PubMed
-
- Chou, S., R. C. Miner, and W. L. Drew. 2000. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J. Infect. Dis. 182:1765-1768. - PubMed
-
- Chou, S., R. H. Waldemer, A. E. Senters, K. S. Michels, G. W. Kemble, R. C. Miner, and W. L. Drew. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169. - PubMed
-
- Ijichi, O., D. Michel, T. Mertens, K. Miyata, and Y. Eizuru. 2002. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antivir. Res. 53:135-142. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources